


FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/644,052	ATTY. DOCKET NO.: C1037.70048US00
		FILING DATE: August 19, 2003	CONFIRMATION NO.: 4791
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1645	EXAMINER: Nina Archie
Sheet		of	2



U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		6,348,312	B1	Peyman et al.	02-19-2002
		6,589,940	B1	Raz et al.	07-08-2003
		6,943,240	B2	Bauer et al.	09-13-2005
		7,176,296	B2	Agrawal et al.	02-13-2007
		7,255,868	B2	Fearon et al.	08-14-2007
		7,271,156	B2	Krieg et al.	07-18-2007
		2003-0129605	A1	Yu et al.	07-10-2003
		2005-0009773	A1	Kandimalla et al.	01-13-2005
		2005-0244380	A1	Krieg et al.	11-03-2005
		2005-0245477	A1	Krieg et al.	11-03-2005
		2006-0019918	A1	Agrawal et al.	01-26-2006
		2007-0184465	A1	Wagner et al.	08-09-2007
		2007-0202128	A1	Krieg et al.	08-30-2007
		2007-0224210	A1	Krieg et al.	09-27-2007
		2007-0232622	A1	Lipford et al.	10-04-2007
		2008-0009455	A9	Krieg et al.	01-10-2008
		2008-0026011	A1	Krieg et al.	01-31-2008
		2008-0031936	A1	Krieg et al.	02-07-2008
		2008-0045473	A1	Uhlmann et al.	02-21-2008

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		WO	98/16247	A1	The Regents of the University of California	04-23-1998	
		WO	98/18810	A1	University of Iowa Research Foundation	05-07-1998	
		WO	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000	
		WO	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000	
		WO	01/22972	A2	Coley Pharmaceuticals, GmbH	04-05-2001	
		WO	01/22990	A2	Coley Pharmaceutical Group, Inc.	04-05-2001	
		WO	03/015711	A2	Coley Pharmaceutical Group, Inc.	02-27-2003	
		WO	03/035836	A2	Hybridon, Inc.	05-01-2003	

EXAMINER: /Nina Archie/	DATE CONSIDERED: 05/14/2008
--------------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/644,052		ATTY. DOCKET NO.: C1037.70048US00	
				FILING DATE: August 19, 2003		CONFIRMATION NO.: 4791	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	2	of	2				

		WO	2004/007743	A2	Coley Pharmaceutical GMBH	01-22-2004	
		WO	2004/026888	A2	Coley Pharmaceutical GMBH	04-01-2004	
		WO	2004/039829	A2	Coley Pharmaceutical Group, Ltd	05-13-2004	
		WO	2004/053104	A2	Coley Pharmaceutical Group, Inc.	06-24-2004	
		WO	2004/087203	A2	Coley Pharmaceutical Group, Ltd.	10-14-2004	
		WO	2004/094671	A2	Coley Pharmaceutical GMBH	11-04-2004	
		WO	2006/080946	A2	Coley Pharmaceutical GMBH	08-03-2006	
		WO	2007/031877	A2	Coley Pharmaceutical GMBH	03-22-2007	
		WO	2007/038720	A2	Coley Pharmaceutical GMBH	04-05-2007	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		GOLDBERG et al., Beyond danger: unmethylated CpG dinucleotides and the immunopathogenesis of disease. Immunol Lett. 2000 Jul 3;73(1):13-8.	
		HARTMANN et al., Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003 Jun;33(6):1633-41.	
		KANDIMALLA et al., Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochem Biophys Res Commun. 2003 Jul 11;306(4):948-53.	
		KRIEG, Now I know my CpGs. Trends Microbiol. 2001 Jun;9(6):249-52.	
		KRUG et al., Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul;31(7):2154-63.	
		MUTWIRI et al., Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol. 2003 Jan 30;91(2):89-103.	
		VOLLMER, CpG motifs to modulate innate and adaptive immune responses. Int Rev Immunol. 2006 May-Aug;25(3-4):125-34.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
/Nina Archie/	05/14/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./